SRTS
ACHAT TOTAL: 171 171 titres (~563 538,30 $ US)
- Insiders
- Sachetta Eric, Sardano Joseph C
- Total bought
- $563,538
- Total sold
- —
- Last activity
- 2026-08-31
- Last synced
-
2026-09-06 09:58:31
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-05
Despite a strong liquidity score (85) and a notable insider cluster buy signal, SRTS's fundamentals are critically impaired — negative margins across the board and a cash conversion cycle exceeding 340 days indicate a…
The first sentence of the analysis written for SRTS on 2026-09-05 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 43.2% | 58.4% | 57.6% | 66.5% | 62.8% | |
| Ebit Margin | -35.0% | 21.6% | 2.7% | 62.9% | 15.2% | |
| Ebitda Margin | -33.6% | 22.6% | 4.6% | 64.0% | 17.5% | |
| Operating Profit Margin | -37.5% | 19.4% | -1.6% | 33.3% | 15.2% | |
| Pretax Profit Margin | -35.0% | 21.6% | 2.7% | 62.9% | 15.2% | |
| Continuous Operations Profit Margin | -28.1% | 15.9% | 2.0% | 54.4% | 15.2% | |
| Net Profit Margin | -28.1% | 15.9% | 2.0% | 54.4% | 15.2% | |
| Bottom Line Profit Margin | -28.1% | 15.9% | 2.0% | 54.4% | 15.2% | |
| Current Ratio | 9.719 | 9.641 | 11.759 | 6.917 | 5.240 | |
| Quick Ratio | 6.635 | 7.925 | 8.943 | 6.462 | 4.945 | |
| Solvency Ratio | -1.484 | 1.117 | 0.194 | 2.856 | 0.760 | |
| Cash Ratio | 4.677 | 3.748 | 5.496 | 3.316 | 2.435 | |
| Price To Earnings Ratio | -8.468 | 16.878 | 79.195 | 5.048 | 28.880 | |
| Price To Earnings Growth Ratio | 0.039 | 0.013 | -0.808 | 0.010 | -0.181 | |
| Forward Price To Earnings Growth Ratio | 0.039 | 0.013 | -0.808 | 0.010 | -0.181 | |
| Price To Earnings Diluted Ratio | -8.468 | 16.878 | 79.195 | 5.082 | 28.880 | |
| Price To Earnings Diluted Growth Ratio | 0.039 | 0.013 | -0.808 | 0.011 | -0.181 | |
| Price To Book Ratio | 1.351 | 2.022 | 0.786 | 2.544 | 4.573 | |
| Price To Sales Ratio | 2.365 | 2.700 | 1.572 | 2.746 | 4.399 | |
| Price To Free Cash Flow Ratio | 195.727 | -101.971 | -16.163 | -77.841 | -287.337 | |
| Price To Operating Cash Flow Ratio | 123.070 | -135.838 | -17.889 | -86.607 | -415.936 | |
| Debt To Assets Ratio | 0.013 | 0.010 | 0.015 | 0.018 | 0.007 | |
| Debt To Equity Ratio | 0.014 | 0.011 | 0.016 | 0.021 | 0.009 | |
| Debt To Capital Ratio | 0.014 | 0.011 | 0.016 | 0.021 | 0.009 | |
| Long Term Debt To Capital Ratio | 0.004 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.103 | 1.114 | 1.100 | 1.180 | 1.239 | |
| Working Capital Turnover Ratio | 0.597 | 0.869 | 0.537 | 1.258 | 1.186 | |
| Operating Cash Flow Ratio | 0.112 | -0.141 | -0.509 | -0.183 | -0.048 | |
| Operating Cash Flow Sales Ratio | 0.019 | -0.020 | -0.088 | -0.032 | -0.011 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.629 | 1.332 | 1.107 | 1.113 | 1.448 | |
| Debt Service Coverage Ratio | -27.989 | 0.000 | 0.000 | 12,377.500 | 91.038 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 7,415.500 | 4,120.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.015 | 0.000 | 0.000 | 0.000 | -5.608 | |
| Operating Cash Flow Coverage Ratio | 0.776 | -1.380 | -2.739 | -1.384 | -1.271 | |
| Capital Expenditure Coverage Ratio | 2.694 | -3.011 | -9.367 | -8.881 | -2.234 | |
| Dividend Paid And Capex Coverage Ratio | 2.694 | -3.011 | -9.367 | -8.881 | -2.234 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -4.717 | 9.671 | 14.382 | 3.431 | 22.109 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 43.2% | ▼-15.3% | ▼-14.5% |
| Ebit Margin | -35.0% | ▼-56.6% | ▼-48.5% |
| Ebitda Margin | -33.6% | ▼-56.2% | ▼-48.6% |
| Operating Profit Margin | -37.5% | ▼-56.9% | ▼-43.3% |
| Pretax Profit Margin | -35.0% | ▼-56.6% | ▼-48.5% |
| Continuous Operations Profit Margin | -28.1% | ▼-44.0% | ▼-40.0% |
| Net Profit Margin | -28.1% | ▼-44.0% | ▼-40.0% |
| Bottom Line Profit Margin | -28.1% | ▼-44.0% | ▼-40.0% |
| Current Ratio | 9.719 | ▲0.078 | ▲1.064 |
| Quick Ratio | 6.635 | ▼-1.291 | ▼-0.347 |
| Solvency Ratio | -1.484 | ▼-2.601 | ▼-2.173 |
| Cash Ratio | 4.677 | ▲0.929 | ▲0.743 |
| Price To Earnings Ratio | -8.468 | ▼-25.346 | ▼-32.775 |
| Price To Earnings Growth Ratio | 0.040 | ▲0.026 | ▲0.225 |
| Forward Price To Earnings Growth Ratio | 0.040 | ▲0.026 | ▲0.225 |
| Price To Earnings Diluted Ratio | -8.468 | ▼-25.346 | ▼-32.781 |
| Price To Earnings Diluted Growth Ratio | 0.040 | ▲0.026 | ▲0.225 |
| Price To Book Ratio | 1.351 | ▼-0.671 | ▼-0.904 |
| Price To Sales Ratio | 2.365 | ▼-0.336 | ▼-0.392 |
| Price To Free Cash Flow Ratio | 195.726 | ▲297.697 | ▲253.244 |
| Price To Operating Cash Flow Ratio | 123.070 | ▲258.909 | ▲229.710 |
| Debt To Assets Ratio | 0.013 | ▲0.003 | ▲0.000 |
| Debt To Equity Ratio | 0.014 | ▲0.003 | -0.000 |
| Debt To Capital Ratio | 0.014 | ▲0.003 | -0.000 |
| Long Term Debt To Capital Ratio | 0.004 | ▲0.004 | ▲0.004 |
| Financial Leverage Ratio | 1.103 | ▼-0.011 | ▼-0.044 |
| Working Capital Turnover Ratio | 0.597 | ▼-0.272 | ▼-0.292 |
| Operating Cash Flow Ratio | 0.112 | ▲0.253 | ▲0.266 |
| Operating Cash Flow Sales Ratio | 0.019 | ▲0.039 | ▲0.045 |
| Free Cash Flow Operating Cash Flow Ratio | 0.629 | ▼-0.703 | ▼-0.497 |
| Debt Service Coverage Ratio | -27.988 | ▼-27.988 | ▼-2516.099 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▼-2307.100 |
| Short Term Operating Cash Flow Coverage Ratio | 2.015 | ▲2.015 | ▲2.734 |
| Operating Cash Flow Coverage Ratio | 0.776 | ▲2.157 | ▲1.976 |
| Capital Expenditure Coverage Ratio | 2.694 | ▲5.705 | ▲6.854 |
| Dividend Paid And Capex Coverage Ratio | 2.694 | ▲5.705 | ▲6.854 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -4.717 | ▼-14.388 | ▼-13.692 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $65.0M | $112.9M | $38.4M | $122.3M | $119.0M | |
| Enterprise value | $43.6M | $91.4M | $16.0M | $97.8M | $104.7M | |
| EV / Sales | 1.59x | 2.19x | 0.66x | 2.20x | 3.87x | |
| EV / Op. cash flow | 82.53x | -110.02x | -7.46x | -69.26x | -365.96x | |
| EV / Free cash flow | 131.26x | -82.59x | -6.74x | -62.25x | -252.81x | |
| EV / EBITDA | -4.72x | 9.67x | 14.38x | 3.43x | 22.11x | |
| Net debt / EBITDA | 2.32x | -2.27x | -20.09x | -0.86x | -3.02x | |
| Current ratio | 9.72x | 9.64x | 11.76x | 6.92x | 5.24x | |
| Income quality | -0.07x | -0.12x | -4.42x | -0.06x | -0.07x | |
| Graham number | — | $6 | $1 | $10 | $3 | |
| Graham net-net | $2 | $2 | $2 | $2 | $1 | |
| Tax burden | 80.2% | 73.7% | 74.4% | 86.6% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $41.2M | $50.9M | $45.3M | $45.5M | $25.3M | |
| Invested capital | $43.6M | $53.4M | $46.6M | $46.8M | $26.2M | |
| Return on assets | -14.6% | 10.7% | 0.9% | 42.7% | 12.8% | |
| Operating ROA | -17.9% | 14.0% | -0.7% | 33.3% | 13.7% | |
| Return on tangible assets | -14.6% | 10.7% | 0.9% | 42.8% | 12.8% | |
| Return on equity | -16.0% | 11.9% | 1.0% | 50.4% | 15.8% | |
| Return on invested capital | -17.0% | 10.6% | -0.6% | 26.1% | 15.5% | |
| Return on capital employed | -21.3% | 14.4% | -0.8% | 30.2% | 15.7% | |
| Earnings yield | -11.9% | 5.9% | 1.3% | 19.8% | 3.5% | |
| Free cash flow yield | 0.5% | -1.0% | -6.2% | -1.3% | -0.3% | |
| Capex / Op. cash flow | 37.1% | -33.2% | -10.7% | -11.3% | -44.8% | |
| Capex / Depreciation | 31.3% | 63.9% | 49.7% | 31.2% | 20.9% | |
| Capex / Sales | 0.7% | 0.7% | 0.9% | 0.4% | 0.5% | |
| SG&A / Sales | 52.4% | 29.0% | 44.1% | 25.5% | 34.9% | |
| R&D / Sales | 28.3% | 10.1% | 15.1% | 7.8% | 12.7% | |
| Stock comp / Sales | 1.1% | 0.8% | 1.3% | 0.4% | 1.5% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.1% | 0.5% | |
| Days sales outstanding | 80d | 172d | 159d | 142d | 164d | |
| Days payables outstanding | 78d | 101d | 99d | 135d | 147d | |
| Operating cycle | 421d | 384d | 578d | 228d | 228d | |
| Cash conversion cycle | 342d | 283d | 479d | 92d | 80d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-42.4%EV / Sales ▼-27.5%EV / EBITDA ▼-148.8%EV / Op. cash flow ▲+192.556Earnings yield ▼-0.178
Profitability
Return on equity ▼-0.280Return on assets ▼-0.252Return on invested capital ▼-0.276Return on capital employed ▼-0.357Operating ROA ▼-0.319Income quality ▲+0.057Tax burden ▲+0.065
Efficiency
Days sales outstanding ▼-92.030Days payables outstanding ▼-22.917Operating cycle ▲+36.282Cash conversion cycle ▲+59.199Capex / Sales ▲+0.001R&D / Sales ▲+0.182
Balance-sheet strength
Current ratio ▲+0.078Net debt / EBITDA ▲+4.586Working capital ▼-9683000.000Invested capital ▼-9833000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-45.4%EV / Sales ▼-59.0%EV / EBITDA ▼-121.3%EV / Op. cash flow ▲+448.491Earnings yield ▼-0.153
Profitability
Return on equity ▼-0.319Return on assets ▼-0.273Return on invested capital ▼-0.326Return on capital employed ▼-0.370Operating ROA ▼-0.316Income quality ▲+0.001Tax burden ▼-0.198
Efficiency
Days sales outstanding ▼-83.492Days payables outstanding ▼-69.179Operating cycle ▲+193.059Cash conversion cycle ▲+262.238Capex / Sales ▲+0.002R&D / Sales ▲+0.156
Balance-sheet strength
Current ratio ▲+4.479Net debt / EBITDA ▲+5.336Working capital ▲+15888000.000Invested capital ▲+17396000.000Intangibles / Total assets ▼-0.005
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-13 Sensus Healthcare Q2 Earnings Call Highlights Sensus Healthcare NASDAQ: SRTS reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier, as delayed third-party financing prevented the company from recognizing revenue tied to eight equipment units before the end of June.
- 2026-08-13 Sensus Healthcare, Inc. (SRTS) Q2 2026 Earnings Call Transcript Sensus Healthcare, Inc. (SRTS) Q2 2026 Earnings Call Transcript
- 2026-08-13 Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of un.
- 2026-07-30 Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026 BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the second quarter of 2026 on Thursday, August 13, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.Participants are enc.